ERBB2 and breast carcinoma: Molecular profiling of cancer has become an integral part of treatment selection and provides predictive and prognostic information, as shown in breast cancer by the immunohistochemical assessment of molecular markers such as estrogen receptor, progesterone receptor, and HER2 (human epidermal growth factor receptor 2) [32].